Peter Sand to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Peter Sand has written about Randomized Controlled Trials as Topic.
Connection Strength
0.166
-
Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. 2009; 27(4):329-39.
Score: 0.063
-
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol. 2005 Jun; 192(6):1849-54; discussion 1854-5.
Score: 0.049
-
Urogynecology: the death of dogma. Int Urogynecol J Pelvic Floor Dysfunct. 2001; 12(1):1-2.
Score: 0.036
-
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011 Sep; 30(7):1214-9.
Score: 0.018